Quarterly ResultMay 7, 2026, 04:25 PM
Codexis Q1 Revenue $15.2M; Net Loss $8.7M; EPS -$0.10
AI Summary
Codexis, Inc. announced its first quarter 2026 financial results, reporting total revenues of $15.2 million, a significant increase from $7.5 million in Q1 2025. The net loss improved substantially to $8.7 million, or $0.10 per share, compared to a net loss of $20.7 million, or $0.25 per share, in the prior year. The company also highlighted key business achievements, including ISO 9001 certification and FDA approval for a supported pharma product, and reiterated its full-year 2026 revenue guidance of $72 million to $76 million, with cash expected to fund operations through the end of 2027.
Key Highlights
- Total revenues for Q1 2026 were $15.2 million, up from $7.5 million in Q1 2025.
- Net loss for Q1 2026 was $8.7 million, or $0.10 per share, compared to $20.7 million, or $0.25 per share, in Q1 2025.
- Product gross margin increased to 71% in Q1 2026 from 55% in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $65.1 million as of March 31, 2026.
- Full-year 2026 revenue guidance reiterated at $72 million to $76 million.
- Received ISO 9001 certification and supported FDA approval for a pharma biocatalysis product.
- Agreed to supply 50g of siRNA using ECO Synthesis for pre-IND studies.
- Expects to apply for a building permit for its ECO GMP Manufacturing Center in Q2 2026.